Company / R&D per Share
Arbutus Biopharma Corp R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$0.13
FY2025
5-year range
$0.13 / $0.73
FY2021-FY2025
Trend
-58.2%
vs FY2024
Sector context
#199 of 208
Health Care
What the data says
Among 208 Health Care companies, Arbutus Biopharma Corp is in the bottom 4% for r&d per share. R&D per Share has declined for 7 consecutive years, from $1.14 in FY2018 to $0.13 in FY2025.
Based on SEC 10-K filings.
0.13 in FY2025 with a 5-year CAGR of -31.6%.
Declined from $0.47 to $0.13 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -38.9%
- 5-Year CAGR
- -31.6%
- 10-Year CAGR
- -
Sector benchmark
Bottom 4% in Health CareTop 96% of 208This company $0.13 Sector average $28.82
▼
-99.5% below sector average
Key checks
Key Insights
- Arbutus Biopharma Corp's r&d per share has declined for 7 consecutive years.
- In FY2025, r&d per share decreased 58.2% year-over-year.
- Ranks #199 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2018.
Company context
Key Data Points
- Altman Z-Score -11.01 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.13 | -58.2% |
| FY2024 | $0.32 | -32.0% |
| FY2023 | $0.47 | -19.6% |
| FY2022 | $0.58 | -20.3% |
| FY2021 | $0.73 | -17.9% |
| FY2020 | $0.89 | -14.8% |
| FY2019 | $1.04 | -8.3% |
| FY2018 | $1.14 | +0.0% |
| FY2017 | $1.14 | +1.9% |
| FY2016 | $1.12 | +18.3% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026